Company Alkermes plc

Equities

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
27.07 USD -0.66% Intraday chart for Alkermes plc +0.37% -2.42%

Business Summary

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Number of employees: 2,100

Sales per Business

USD in Million2022Weight2023Weight Delta
Product
55.3 %
778 69.9 % 920 55.3 % +18.32%
Manufacturing and Royalty
44.7 %
332 29.9 % 743 44.7 % +123.92%
Research and Development
0.0 %
0 0.0 % 0 0.0 % -92.69%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
89.7 %
932 83.8 % 1,492 89.7 % +60.08%
Rest of World
10.2 %
178 16.0 % 170 10.2 % -4.32%
Ireland
0.1 %
2 0.2 % 1 0.1 % -35.54%

Managers

Managers TitleAgeSince
Chief Executive Officer 62 91-01-31
Director of Finance/CFO 51 98-12-31
President 61 11-08-31
Chief Tech/Sci/R&D Officer - 19-06-30
Chief Tech/Sci/R&D Officer 56 17-05-29
Chief Tech/Sci/R&D Officer - 04-12-31
Chief Tech/Sci/R&D Officer - 16-12-31
Chief Operating Officer - 11-08-31
Compliance Officer 52 16-04-30
Chief Tech/Sci/R&D Officer - -

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 62 91-01-31
Director/Board Member 72 16-05-25
Director/Board Member 62 20-12-09
Director/Board Member - 20-12-09
Director/Board Member 61 11-08-31
Director/Board Member 65 19-09-11
Director/Board Member 65 21-11-17
Director/Board Member 58 22-05-23
Director/Board Member 74 19-09-11
Director/Board Member 49 21-05-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 172,665,351 164,825,866 ( 95.46 %) 5,589,218 ( 3.237 %) 95.46 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
16.93 %
28,284,283 16.93 % 840 M $
Vanguard Fiduciary Trust Co.
12.54 %
20,955,454 12.54 % 622 M $
Wellington Management Co. LLP
9.122 %
15,241,470 9.122 % 453 M $
9,352,970 5.598 % 278 M $
Renaissance Technologies LLC
3.621 %
6,049,317 3.621 % 180 M $
Hardman Johnston Global Advisors LLC
3.278 %
5,476,255 3.278 % 163 M $
Pictet Asset Management Holding SA
3.175 %
5,304,613 3.175 % 157 M $
Deep Track Capital LP
2.394 %
4,000,000 2.394 % 119 M $
RTW Investments LP
2.335 %
3,901,523 2.335 % 116 M $
Geode Capital Management LLC
2.178 %
3,638,089 2.178 % 108 M $

Company contact information

Alkermes Plc

Connaught House 1 Burlington Road

4, Dublin

+

http://www.alkermes.com
address Alkermes plc(ALKS)